Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.
Journal: Addiction biology
Published: January 14, 2019
Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist.
Journal: Pharmacology research & perspectives
Published: October 07, 2015
Commentary: larazotide acetate - an exciting new development for coeliac patients? Authors' reply.
Journal: Alimentary pharmacology & therapeutics
Published: December 09, 2012
Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study.
Journal: Alimentary pharmacology & therapeutics
Published: September 11, 2012
A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge.
Journal: The American journal of gastroenterology
Published: July 25, 2012
Larazotide acetate regulates epithelial tight junctions in vitro and in vivo.
Journal: Peptides
Published: December 13, 2011
Showing 1-6 of 6
Last Updated: 09/26/2026